2024-515434-32-00招募中2 期
TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 26
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Pr Benoit YOU
Scientific
Hospices Civils De Lyon
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
1 期
TROPHIMMUN, a phase II trial of avelumab in chemo-resistant gestational trophoblastic neoplasias (GTN)Gestational trophoblastic neoplasiasMedDRA version: 19.0Level: PTClassification code 10061988Term: Gestational trophoblastic tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002322-37-FRHospices Civils de Lyon
招募中
2 期
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors2023-509716-29-00Enliven Therapeutics Inc.156
招募中
不适用
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaNCT07268131Fudan University30
招募中
3 期
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in late-stage lung cancer patients.2024-513621-23-00Immutep363
招募中
3 期
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study2023-506632-32-00Gruppo Oncologico Del Nord Ovest238